Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 569

1.

Chronotropic Response and Cognitive Function in a Cohort at Risk for Alzheimer's Disease.

Law LL, Schultz SA, Boots EA, Einerson JA, Dougherty RJ, Oh JM, Korcarz CE, Edwards DF, Koscik RL, Dowling NM, Gallagher CL, Bendlin BB, Carlsson CM, Asthana S, Hermann BP, Sager MA, Johnson SC, Cook DB, Stein JH, Okonkwo OC.

J Alzheimers Dis. 2016 Dec 1. [Epub ahead of print]

PMID:
27911299
2.

Label-free quantitative comparison of cerebrospinal fluid glycoproteins and endogenous peptides in subjects with alzheimer's disease, mild cognitive impairment and healthy individuals.

Wang J, Cunningham R, Zetterberg H, Asthana S, Carlsson C, Okonkwo O, Li L.

Proteomics Clin Appl. 2016 Nov 9. doi: 10.1002/prca.201600009. [Epub ahead of print]

PMID:
27863112
3.

Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease.

Dean DC 3rd, Hurley SA, Kecskemeti SR, O'Grady JP, Canda C, Davenport-Sis NJ, Carlsson CM, Zetterberg H, Blennow K, Asthana S, Sager MA, Johnson SC, Alexander AL, Bendlin BB.

JAMA Neurol. 2016 Nov 14. doi: 10.1001/jamaneurol.2016.3232. [Epub ahead of print]

PMID:
27842175
4.

The 2015 National Cancer Program in Sweden: Introducing standardized care pathways in a decentralized system.

Wilkens J, Thulesius H, Schmidt I, Carlsson C.

Health Policy. 2016 Oct 18. pii: S0168-8510(16)30238-X. doi: 10.1016/j.healthpol.2016.09.008. [Epub ahead of print]

5.

Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology.

Schmitz TW, Nathan Spreng R; Alzheimer's Disease Neuroimaging Initiative..

Nat Commun. 2016 Nov 4;7:13249. doi: 10.1038/ncomms13249.

6.

Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer's disease.

Zhang X, Mormino EC, Sun N, Sperling RA, Sabuncu MR, Yeo BT; Alzheimer’s Disease Neuroimaging Initiative..

Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6535-E6544.

7.

Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's Disease.

Racine AM, Clark LR, Berman SE, Koscik RL, Mueller KD, Norton D, Nicholas CR, Blennow K, Zetterberg H, Jedynak B, Bilgel M, Carlsson CM, Christian BT, Asthana S, Johnson SC.

J Alzheimers Dis. 2016 Oct 18;54(4):1395-1408.

8.

Age-Related Sensory Impairments and Risk of Cognitive Impairment.

Fischer ME, Cruickshanks KJ, Schubert CR, Pinto AA, Carlsson CM, Klein BE, Klein R, Tweed TS.

J Am Geriatr Soc. 2016 Oct;64(10):1981-1987. doi: 10.1111/jgs.14308.

PMID:
27611845
9.

Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid-β Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimer's Disease.

Darst BF, Koscik RL, Racine AM, Oh JM, Krause RA, Carlsson CM, Zetterberg H, Blennow K, Christian BT, Bendlin BB, Okonkwo OC, Hogan KJ, Hermann BP, Sager MA, Asthana S, Johnson SC, Engelman CD.

J Alzheimers Dis. 2016 Nov 19;55(2):473-484.

10.

Morphometricity as a measure of the neuroanatomical signature of a trait.

Sabuncu MR, Ge T, Holmes AJ, Smoller JW, Buckner RL, Fischl B; Alzheimer's Disease Neuroimaging Initiative..

Proc Natl Acad Sci U S A. 2016 Sep 27;113(39):E5749-56. doi: 10.1073/pnas.1604378113.

11.

Changes in intracranial venous blood flow and pulsatility in Alzheimer's disease: A 4D flow MRI study.

Rivera-Rivera LA, Schubert T, Turski P, Johnson KM, Berman SE, Rowley HA, Carlsson CM, Johnson SC, Wieben O.

J Cereb Blood Flow Metab. 2016 Aug 4. pii: 0271678X16661340. [Epub ahead of print]

PMID:
27492950
12.

Meeting physical activity recommendations may be protective against temporal lobe atrophy in older adults at risk for Alzheimer's disease.

Dougherty RJ, Ellingson LD, Schultz SA, Boots EA, Meyer JD, Lindheimer JB, Van Riper S, Stegner AJ, Edwards DF, Oh JM, Koscik RL, Dowling MN, Gallagher CL, Carlsson CM, Rowley HA, Bendlin BB, Asthana S, Hermann BP, Sager MA, Johnson SC, Okonkwo OC, Cook DB.

Alzheimers Dement (Amst). 2016 Apr 9;4:14-7. doi: 10.1016/j.dadm.2016.03.005.

13.

Insulin resistance is associated with lower arterial blood flow and reduced cortical perfusion in cognitively asymptomatic middle-aged adults.

Hoscheidt SM, Kellawan JM, Berman SE, Rivera-Rivera LA, Krause RA, Oh JM, Beeri MS, Rowley HA, Wieben O, Carlsson CM, Asthana S, Johnson SC, Schrage WG, Bendlin BB.

J Cereb Blood Flow Metab. 2016 Aug 3. pii: 0271678X16663214. [Epub ahead of print]

PMID:
27488909
14.

Polygenic risk of Alzheimer disease is associated with early- and late-life processes.

Mormino EC, Sperling RA, Holmes AJ, Buckner RL, De Jager PL, Smoller JW, Sabuncu MR; Alzheimer's Disease Neuroimaging Initiative..

Neurology. 2016 Aug 2;87(5):481-8. doi: 10.1212/WNL.0000000000002922.

PMID:
27385740
15.

Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis.

Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Pérez JM, Evans AC; Alzheimer’s Disease Neuroimaging Initiative..

Nat Commun. 2016 Jun 21;7:11934. doi: 10.1038/ncomms11934.

16.

Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife.

Racine AM, Koscik RL, Berman SE, Nicholas CR, Clark LR, Okonkwo OC, Rowley HA, Asthana S, Bendlin BB, Blennow K, Zetterberg H, Gleason CE, Carlsson CM, Johnson SC.

Brain. 2016 Aug;139(Pt 8):2261-74. doi: 10.1093/brain/aww142.

PMID:
27324877
17.

A semi-mechanism approach based on MRI and proteomics for prediction of conversion from mild cognitive impairment to Alzheimer's disease.

Liu H, Zhou X, Jiang H, He H, Liu X; Alzheimer’s Disease Neuroimaging Initiative..

Sci Rep. 2016 Jun 7;6:26712. doi: 10.1038/srep26712.

18.

Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer's disease cohorts.

Tan L, Wang HF, Tan MS, Tan CC, Zhu XC, Miao D, Yu WJ, Jiang T, Tan L, Yu JT; Alzheimer’s Disease Neuroimaging Initiative..

Sci Rep. 2016 May 27;6:26027. doi: 10.1038/srep26027.

19.

Mild Cognitive Impairment in Late Middle Age in the Wisconsin Registry for Alzheimer's Prevention Study: Prevalence and Characteristics Using Robust and Standard Neuropsychological Normative Data.

Clark LR, Koscik RL, Nicholas CR, Okonkwo OC, Engelman CD, Bratzke LC, Hogan KJ, Mueller KD, Bendlin BB, Carlsson CM, Asthana S, Sager MA, Hermann BP, Johnson SC.

Arch Clin Neuropsychol. 2016 May 8. pii: acw024. [Epub ahead of print]

PMID:
27193363
20.

Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology.

Insel PS, Mattsson N, Mackin RS, Schöll M, Nosheny RL, Tosun D, Donohue MC, Aisen PS, Jagust WJ, Weiner MW; Alzheimer's Disease Neuroimaging Initiative..

Neurology. 2016 May 17;86(20):1887-96. doi: 10.1212/WNL.0000000000002683.

PMID:
27164667
Items per page

Supplemental Content

Loading ...
Support Center